Live Cell Painting: Better Drug Insights Start Here
"ChromaLIVE™ has transformed our cell screening workflows, allowing to identify novel hits and mechanistic insights"
Download our Guide. Learn how ChromaLIVE™ non-toxic dye supercharges cell painting
✓ Boost hit detection: +85% over traditional cell painting
✓ Improve MoA Elucidation: +10% over traditional cell painting
✓ Avoid disrupting drug profiles with washing, fixation and “live-cell” (but toxic) dyes.
✓ More datapoints, better insights with kinetics.
✓ No wash, no fixation, no plate copies.
Download our guide to learn more!
Dr. Simon Mathien, HTS Platform Lead Institute for Research in Immunology and Cancer (IRIC), UdeM
"ChromaLIVE™ has completely transformed our cell screening workflows. Its non-toxic nature and wash-free protocol means we can get similar data to cell painting, but with additional insights - and that’s without accounting for kinetic data that ChromaLIVE™ adds to these insights. This new tool has allowed us to identify novel hits and mechanistic insights into compound series from prior campaigns”
Dr. David Andrews, Director and Senior Scientist, Biological Sciences, Sunnybrook Research Institute
"The unbiased, data-rich insights provided by ChromaLIVE™ have been a game-changer in stratifying CLL patient cohorts.
By leveraging ChromaLIVE's non-toxic, and data-rich capabilities, we were able to perform high-content phenotypic analysis on primary patient samples and identify new patient cohorts with predictable drug responses, something not possible with conventional clinical criteria or traditional in vitro assays that use antibody-based immunofluorescence."
Dr. Magnar Bjørås, Professor of Medicine at NTNU
"After testing the Saguaro dyes, we immediately saw the value in changing the way we screen for drugs in our 3D organoid systems.
Saguaro's dyes allowed us to stain and visualize 3D organoid systems including eye, heart, and brain without compromising cell health. NucleoLIVE™, MortaLIVE™ and ChromaLIVE™ showed superior penetration compared to other commercial dyes, enabling clear visualization of cells in the organoid core, which is critical for monitoring cell death and the effects of hypoxia and hypoxia-ischemia across organoid models."
Special mention to Jing Ye, Project Leader, and to María Cámara Quílez, Post-Doctoral Scientist working in Magnar's lab.
Other drug discovery leaders who have used ChromaLIVE™ for their cell painting assays
Learn More
-
ChromaLIVE™ is used by drug discovery leaders to generate better drug insights for their cell painting assays.
ChromaLIVE™ is the only non-toxic live cell painting method. Beyond new kinetic insights from real-time data, it provides enhanced cell painting data even at single time points, in a wash-free and non-toxic manner. This makes ChromaLIVE™ the ideal tool for screening drugs in physiologically relevant models, and in an effortless way, ultimately generating better drug annotations.
-
ChromaLIVE™ is the leading technology for profiling drugs with images. It is a data-rich, non-toxic dye that allows cells to reveal their unique phenotypes in their live, native environment for optimal physiological relevance.
ChromaLIVE™ reports on mitochondrial energetics and stains multiple intracellular membranes of viable and dead cells
-
RNA sequencing data and week-long cell cultures in sensitive cell models support this claim.
Whole-genome RNA sequencing and proteomics data show unperturbed expression patterns – in contrast with alternative live cell dyes – for cells cultured in presence of ChromaLIVE™.
In addition, ChromaLIVE™ has been successfully tested in sensitive cell models without affecting cell health for weeks on end. For instance, it has been used in a 3-week culture of iPSC-derived neurons, and a 6-week culture of patient-derived prostate cancer organoids.
-
ChromaLIVE™ appears in multiple peer-reviewed publications, including:
- Anne Carpenter and Beth Cimini lab at the Broad Institute of MIT and Harvard on comparing cell painting and ChromaLIVE™, 2024
- Gregory Way Lab at University of Colorado Anschutz, on using ChromaLIVE™ to predict cell death before it occurs, 2025
- Plexium SLAS Discovery, on showing the capabilities and biological inertness of ChromaLIVE™, 2024
- Gaetan Laroche Lab at Université Laval, on using ChromaLIVE™ as a tool for accurately tracking stem cell differentiation in real-time, 2025
- Book on High Content Imaging in Drug Discovery, presenting ChromaLIVE™ as a state-of-the-art tool for phenotypic drug discovery, 2025
- David Andrews Lab at Sunnybrook Research Institute, on using ChromaLIVE™ to make CLL patient stratification possible, where standard clinical biomarkers fail, 2025
Intéressé par ChromaLIVE™?
Rejoignez les plus de 200 leaders en découverte de médicaments qui obtiennent de la nouvelle donnée en cell painting
